
DEA Warns 'Synthetic Soup' of Fentanyl Mixtures Is Overwhelming Naloxone
Law enforcement reports fentanyl increasingly combined with xylazine, medetomidine, nitazenes and cychlorphine—substances that resist naloxone reversal.
Evidence-based articles, treatment guides, and the latest news in addiction recovery and mental health.

Law enforcement reports fentanyl increasingly combined with xylazine, medetomidine, nitazenes and cychlorphine—substances that resist naloxone reversal.

First randomized double-blind study in Sweden finds psilocybin provides clinically meaningful depression relief within days, with 53% remission rate at six weeks.

Senate Bill 249 decriminalizes drug paraphernalia possession and expands sterile supply distribution, sparking disagreement over public safety and addiction treatment approaches.

UC San Francisco and Imperial College London researchers discover that one 25mg dose of psilocybin creates measurable anatomical brain changes lasting at least a month.
Michigan Attorney General Dana Nessel unveils comprehensive spending guidance and public reporting tools to ensure opioid settlement funds reach communities in need.

Despite rapid expansion of telehealth mental health services, a major JAMA study reveals only modest gains in reaching rural and underserved patients.

State auditor finds Arizona Department of Corrections may have unlawfully spent opioid settlement money without proving inmates contracted hepatitis C from IV drug use.

CDC reports nearly 70,000 overdose deaths in 2025, a 14% drop and the longest sustained decline in decades, though challenges remain in several states.

As overdose deaths finally begin to fall, a new class of ultra-potent synthetic opioids is emerging in the US drug supply, presenting unprecedented challenges for detection and treatment.